{
    "organizations": [],
    "uuid": "746df1d12f82df50ddfd3702d954148b3ee70a1b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-announces-l/brief-mithra-pharmaceuticals-announces-last-subject-completes-donesta-phase-ii-study-idUSFWN1PK03K",
    "ord_in_thread": 0,
    "title": "BRIEF-Mithra Pharmaceuticals Announces Last Subject Completes Donesta Phase II Study​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* ‍MITHRA ANNOUNCES LAST SUBJECT COMPLETES DONESTA® PHASE II STUDY​\n* ‍PHASE II STUDY ON TRACK TO YIELD TOP LINE DATA LATE Q1 2018​\n* ‍260 WOMEN RECRUITED, OVER 200 COMPLETED AT LEAST 12 WEEKS OF TREATMENT IN PHASE II STUDY​\n* ‍12-WEEK DATA GENERATED FOR ADDITIONAL 15% OF SUBJECTS TO IMPROVE ROBUSTNESS OF ANALYSIS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-25T17:21:00.000+02:00",
    "crawled": "2018-01-26T21:30:47.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "mithra",
        "pharmaceutical",
        "sa",
        "announces",
        "last",
        "subject",
        "completes",
        "phase",
        "ii",
        "ii",
        "study",
        "track",
        "yield",
        "top",
        "line",
        "data",
        "late",
        "q1",
        "woman",
        "recruited",
        "completed",
        "least",
        "week",
        "treatment",
        "phase",
        "ii",
        "data",
        "generated",
        "additional",
        "subject",
        "improve",
        "robustness",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}